207 related articles for article (PubMed ID: 12743133)
1. Use of CA-125 to assess response to new agents in ovarian cancer trials.
Rustin GJ
J Clin Oncol; 2003 May; 21(10 Suppl):187s-193s. PubMed ID: 12743133
[TBL] [Abstract][Full Text] [Related]
2. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide.
Rustin GJ; Timmers P; Nelstrop A; Shreeves G; Bentzen SM; Baron B; Piccart MJ; Bertelsen K; Stuart G; Cassidy J; Eisenhauer E
J Clin Oncol; 2006 Jan; 24(1):45-51. PubMed ID: 16382112
[TBL] [Abstract][Full Text] [Related]
3. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy.
Liu PY; Alberts DS; Monk BJ; Brady M; Moon J; Markman M
J Clin Oncol; 2007 Aug; 25(24):3615-20. PubMed ID: 17704410
[TBL] [Abstract][Full Text] [Related]
4. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.
Tuxen MK; Sölétormos G; Dombernowsky P
Br J Cancer; 2001 May; 84(10):1301-7. PubMed ID: 11355938
[TBL] [Abstract][Full Text] [Related]
5. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?
Gronlund B; Høgdall C; Hilden J; Engelholm SA; Høgdall EV; Hansen HH
J Clin Oncol; 2004 Oct; 22(20):4051-8. PubMed ID: 15364966
[TBL] [Abstract][Full Text] [Related]
6. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.
Markman M
Gynecol Oncol; 2009 Jul; 114(1):136-7; authore reply 137. PubMed ID: 19138792
[No Abstract] [Full Text] [Related]
7. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).
Rustin GJ; Vergote I; Eisenhauer E; Pujade-Lauraine E; Quinn M; Thigpen T; du Bois A; Kristensen G; Jakobsen A; Sagae S; Greven K; Parmar M; Friedlander M; Cervantes A; Vermorken J;
Int J Gynecol Cancer; 2011 Feb; 21(2):419-23. PubMed ID: 21270624
[TBL] [Abstract][Full Text] [Related]
8. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.
Gossner G; Coleman RL; Mutch DG; Horowitz NS; Rader JS; Gibb RK; Powell MA; Herzog TJ
Gynecol Oncol; 2006 Oct; 103(1):212-8. PubMed ID: 16677696
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.
Markman M; Liu PY; Rothenberg ML; Monk BJ; Brady M; Alberts DS
J Clin Oncol; 2006 Mar; 24(9):1454-8. PubMed ID: 16549840
[TBL] [Abstract][Full Text] [Related]
10. Declining CA-125 in an ovarian cancer patient with progression of measurable disease: a rational hypothesis for discordant results.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2000 May; 77(2):321-2. PubMed ID: 10785487
[TBL] [Abstract][Full Text] [Related]
11. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.
Gadducci A; Cosio S; Fanucchi A; Negri S; Cristofani R; Genazzani AR
Gynecol Oncol; 2004 Apr; 93(1):131-6. PubMed ID: 15047226
[TBL] [Abstract][Full Text] [Related]
12. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
Bădulescu F; Bădulescu A; Schenker M; Popescu CF; Stoica Z
Rom J Morphol Embryol; 2005; 46(4):329-34. PubMed ID: 16688372
[TBL] [Abstract][Full Text] [Related]
13. Second-line chemotherapy of epithelial ovarian cancer.
Markmon M
Expert Rev Anticancer Ther; 2003 Feb; 3(1):31-6. PubMed ID: 12597347
[TBL] [Abstract][Full Text] [Related]
14. New, expanded, and modified use of approved antineoplastic agents in ovarian cancer.
Markman M
Oncologist; 2007 Feb; 12(2):186-90. PubMed ID: 17296814
[TBL] [Abstract][Full Text] [Related]
15. [Second-line chemotherapy and new drugs for ovarian carcinoma].
Priolo D; Antonelli G; Calì S; Colina P; Giuffrida D; Malaponte E; Mattina M; Parisi A; Sambataro D; Vitale F; Ferraù F
Clin Ter; 2001; 152(1):39-50. PubMed ID: 11382169
[TBL] [Abstract][Full Text] [Related]
16. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials.
Rustin GJ; Nelstrop AE; Bentzen SM; Bond SJ; McClean P
J Clin Oncol; 2000 Apr; 18(8):1733-9. PubMed ID: 10764434
[TBL] [Abstract][Full Text] [Related]
17. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.
Smyth JF; Gourley C; Walker G; MacKean MJ; Stevenson A; Williams AR; Nafussi AA; Rye T; Rye R; Stewart M; McCurdy J; Mano M; Reed N; McMahon T; Vasey P; Gabra H; Langdon SP
Clin Cancer Res; 2007 Jun; 13(12):3617-22. PubMed ID: 17575226
[TBL] [Abstract][Full Text] [Related]
18. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
[TBL] [Abstract][Full Text] [Related]
19. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer.
Rustin GJ; Bast RC; Kelloff GJ; Barrett JC; Carter SK; Nisen PD; Sigman CC; Parkinson DR; Ruddon RW
Clin Cancer Res; 2004 Jun; 10(11):3919-26. PubMed ID: 15173101
[No Abstract] [Full Text] [Related]
20. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range.
Santillan A; Garg R; Zahurak ML; Gardner GJ; Giuntoli RL; Armstrong DK; Bristow RE
J Clin Oncol; 2005 Dec; 23(36):9338-43. PubMed ID: 16361633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
